search
Back to results

Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
EUFLEXXA
Sponsored by
Georgia Institute for Clinical Research, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

30 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Be age 30 to 79
  2. Give written informed consent for trial participation
  3. Must have shoulder pain for a minimum of 6 months but less than 5 years
  4. Must have a Pain Intensity Score of > 5
  5. Must be willing to discontinue all pain medications 24 hours prior to each clinic visit
  6. Must have a stable pain medication regime 1 month prior to treatment
  7. Agrees to maintain pain medication doses within 30% (increase or decrease) of the Baseline dose

Exclusion Criteria:

  1. Any history of full thickness rotator cuff tear or joint effusion
  2. A diagnosis of chronic acromioclavical disease, active epicondylitis, or active Carpal Tunnel Disease
  3. Has had more than 2 corticosteroid injections in the previous 3 months
  4. Has an infection or an inflammatory condition of the trial shoulder
  5. Has acute or inflammatory arthropathy in the trial shoulder, e.g. gouty arthritis, psoriatic arthritis or rheumatoid arthritis. Has a history of systemic inflammatory arthropathies, e.g. polyarthritis, rheumatoid arthritis, psoriatic arthritis or gout
  6. Has severe joint effusion of the trial shoulder
  7. Has a diagnosis of cancer within the past 5 years (basal cell carcinoma is not excluded)
  8. Has had any hyaluronate agent or other chondroprotective agents in the trial shoulder
  9. Has a hypersensitivity to HA products, eggs, birds or feathers
  10. Has a history of substance abuse, alcohol abuse or psychiatric condition, that in the opinion of the Investigator, will potentially interfere with participation
  11. Has any medical condition that may increase the risk associated with intra-articular injections, to include (but are not limited to): thrombocytopenia, blood disorders treated with warfarin or anticoagulants, anemia or other concomitant diseases that, in the opinion of the Investigator, will interfere with the evaluation of the trial treatment, e.g., renal or liver disease, uncontrolled diabetes, significant cardiovascular, immune deficiency, or infectious disease
  12. Is actively involved in a litigation involving Workers' Compensation
  13. Is a female that is pregnant, planning to become pregnant or is lactating
  14. Has participated in a clinical trial within the past four weeks

Sites / Locations

  • Georgia Institute for Clinical Research, LLC

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EUFLEXXA

Arm Description

ACTIVE CONTROL

Outcomes

Primary Outcome Measures

Number of Participants With a Reduction in Pain by the Scores.
Greater than 50 percent reduction in pain scores from baseline.

Secondary Outcome Measures

Full Information

First Posted
August 31, 2009
Last Updated
March 27, 2013
Sponsor
Georgia Institute for Clinical Research, LLC
Collaborators
Ferring Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT00969501
Brief Title
Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)
Official Title
Investigator Initiated, Exploratory Case Study Three Injections of EUFLEXXA (Sodium Hyaluronate)Treatment of Chronic Shoulder Pain Associated With Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Georgia Institute for Clinical Research, LLC
Collaborators
Ferring Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The hypothesis of this study is that by using 3 injections of EUFLEXXA, there will be an improvement in pain levels and range of motion.
Detailed Description
To demonstrate that EUFLEXXA is safe for the treatment of chronic shoulder pain associated with osteoarthritis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EUFLEXXA
Arm Type
Experimental
Arm Description
ACTIVE CONTROL
Intervention Type
Drug
Intervention Name(s)
EUFLEXXA
Intervention Description
2.5 mL of EUFLEXXA (per injection) x 3 injections
Primary Outcome Measure Information:
Title
Number of Participants With a Reduction in Pain by the Scores.
Description
Greater than 50 percent reduction in pain scores from baseline.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be age 30 to 79 Give written informed consent for trial participation Must have shoulder pain for a minimum of 6 months but less than 5 years Must have a Pain Intensity Score of > 5 Must be willing to discontinue all pain medications 24 hours prior to each clinic visit Must have a stable pain medication regime 1 month prior to treatment Agrees to maintain pain medication doses within 30% (increase or decrease) of the Baseline dose Exclusion Criteria: Any history of full thickness rotator cuff tear or joint effusion A diagnosis of chronic acromioclavical disease, active epicondylitis, or active Carpal Tunnel Disease Has had more than 2 corticosteroid injections in the previous 3 months Has an infection or an inflammatory condition of the trial shoulder Has acute or inflammatory arthropathy in the trial shoulder, e.g. gouty arthritis, psoriatic arthritis or rheumatoid arthritis. Has a history of systemic inflammatory arthropathies, e.g. polyarthritis, rheumatoid arthritis, psoriatic arthritis or gout Has severe joint effusion of the trial shoulder Has a diagnosis of cancer within the past 5 years (basal cell carcinoma is not excluded) Has had any hyaluronate agent or other chondroprotective agents in the trial shoulder Has a hypersensitivity to HA products, eggs, birds or feathers Has a history of substance abuse, alcohol abuse or psychiatric condition, that in the opinion of the Investigator, will potentially interfere with participation Has any medical condition that may increase the risk associated with intra-articular injections, to include (but are not limited to): thrombocytopenia, blood disorders treated with warfarin or anticoagulants, anemia or other concomitant diseases that, in the opinion of the Investigator, will interfere with the evaluation of the trial treatment, e.g., renal or liver disease, uncontrolled diabetes, significant cardiovascular, immune deficiency, or infectious disease Is actively involved in a litigation involving Workers' Compensation Is a female that is pregnant, planning to become pregnant or is lactating Has participated in a clinical trial within the past four weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arnold J. Weil, M.D.
Organizational Affiliation
Georgia Institute for Clinical Research, LLC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Georgia Institute for Clinical Research, LLC
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)

We'll reach out to this number within 24 hrs